Antibacterial Agents TRIZ Cases

Anhydrous calcium hydrogen phosphate and microcrystalline cellulose diluents improve fosfomycin trometamol tablet stability, flow, and palatability.

Self-assembling peptides anchor to tissue edges and accelerate hemostasis, reducing fluid leakage in leaky gut conditions.

A dental sealant composition releases arginine and fluoride to protect tooth enamel.

A silver-containing agent combined with an organoselenium agent targets bacterial thioredoxin systems to inhibit growth.

Segmenting antibiotic function with heterocyclic inhibitors overcomes bacterial resistance by protecting beta-lactams from enzymatic degradation.

Stabilized Echinacea angustifolia cell cultures produce high titer caffeoylquinic acids via controlled fermentation and resin extraction.

A chimeric polypeptide links two specific amino acid sequences to stimulate protective T-cell and B-cell immune responses against Chlamydia trachomatis.

Fluoroalkoxycombretastatin derivatives overcome drug resistance by enhancing tubulin inhibition via specific B-ring fluorination.

FK506 derivatives treat fungal infections by providing broad-spectrum efficacy without severe toxicity.

A multivalent vaccine combines live attenuated Shigella strains with ETEC surface antigen CS14 to induce protective antibodies.

Bambermycin compounds address unidentified ERE pathogens by reducing morbidity and mortality rates.

Doxycycline hyclate and triamcinolone acetonide in endodontic medicaments eliminate tooth staining while maintaining prolonged antibacterial substantivity.

A nutritional composition for companion animals using specific protein, carbohydrate, and vegetable sources to support lean body mass.

Azabenzothiophenyl compounds address insufficient therapeutic effectiveness by inhibiting MEK kinase function to treat hyperproliferative disorders.

Multi-step chromatography purifies inter-alpha inhibitor proteins to 85% purity, extending half-life and improving survival rates in septic shock models.

A prophylactic nasal spray delivers povidone iodine to coat the nasal mucosa and inhibit microbial entry.

Self-emulsifying carriers protect amphotericin B from gastric degradation, enabling oral administration and reducing renal toxicity.

Negative-charged liposomes target bone marrow while minimizing tumor uptake, enabling high-resolution PET imaging and effective radioprotection.

A non-pathogenic bacterium expressing a MAM polypeptide blocks initial host binding of pathogenic bacteria.

Fusing an antibody mimetic to a colicin creates a conjugate that forms ion channels in bacterial membranes, bypassing resistance mechanisms.

Macrocyclic compounds activate the STING pathway, resolving specificity and efficacy limitations of existing agonists to enhance immune responses.

Liquid Hib reconstitutes lyophilized meningococcal antigen, resolving stability and immunological interference in combination vaccines.

Adding negatively charged polymers to cationic conjugates reduces cell toxicity while maintaining delivery efficiency for genetic disorders.

Polyclonal antibodies targeting IL-18 receptor subunits inhibit signaling to suppress epidermal thickening.

Low afucosylation on the Fc region preserves therapeutic efficacy while preventing antibody-dependent cellular cytotoxicity.

TNFR2 agonists expand CD4+CD25hi Tregs into homogeneous populations, resolving impurity risks from heterogeneous ex vivo cultures.

T145 oxazolidinone targets resistant Mycobacterium tuberculosis strains, offering a potent therapeutic alternative to existing antibiotics.

Laser ablation marks frozen vials inside a dry nitrogen enclosure, preserving biological activity by avoiding heat stress during labeling.

Nanobubble water precipitates pharmaceutical compounds into microparticulate solids, eliminating post-treatment steps and reducing production complexity.

Targeting the SdrF adhesin with monoclonal antibodies prevents initial bacterial adherence to biomaterials, addressing nosocomial infection risks.

A bispecific antibody binds human TLR2 and TLR4 receptors to inhibit inflammatory responses.

RecA inhibitors disable bacterial DNA repair mechanisms, enabling lower antibiotic doses that overcome resistance while reducing toxicity.

Multi-antibody compositions merge specificities to resolve the contradiction between neutralization potency and cross-serotype coverage.

Anti-MIF antibodies target macrophage migration inhibitory factor to block cardiodepressant signaling pathways in septic shock patients.

A reservoir layer forms from a polymeric metal astringent and anionic surfactant to deliver continuous antimicrobial agents, reducing labor costs.

Fully human engineered anti-IL-6 antibodies reduce immunogenicity and serum sickness risks, enabling lower dosages for safer rheumatoid arthritis treatment.

Stable LytM catalytic domain enables bacterial lysis and protein purification under low salt conditions where conventional enzymes fail.

Hybrid compounds overcome antibiotic resistance by targeting planktonic and biofilm bacteria to resolve chronic infections.

Reduced nicotinamide riboside resolves immunity reliability by boosting macrophages to clear pathogens and limit pathology.

Inactivating the ipdAB operon reduces macrophage survival and virulence while maintaining immunogenicity for safe animal protection.

Pre-weaning probiotic administration reduces fecal shedding of ETEC F18 and toxin, lowering antibiotic reliance.

Dual acylation via bis-amino linker extends GLP-1 half-life for monthly dosing while maintaining receptor binding potency.

Hexane solvent extracts lipophilic compounds from Picrorhiza plant matter, removing non-lipophilic constituents that mask therapeutic efficacy.

Engineered antimicrobial peptides disrupt bacterial membranes to reduce viable counts, addressing antibiotic resistance in food safety.

Indolizine derivatives selectively inhibit PI3Kδ and γ isoforms, resolving the contradiction between broad-spectrum activity and specific treatment outcomes.

Benzimidazolylidene rhenium complexes overcome high molecular weight constraints to provide novel antibacterial agents.

Salvia plebeia extract blocks PD-L1 and PD-1 interaction to activate T cells, reducing normal cell damage from chemotherapy.

Antisense oligonucleotides bind natural antisense transcripts to resolve the contradiction between gene expression efficiency and sequence specificity.